Abstract
All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Current Pharmaceutical Design
Title:Inflammatory Mediators in Epilepsy
Volume: 19 Issue: 38
Author(s): Lourdes Lorigados Pedre, Lilia M Morales Chacón, Sandra Orozco Suárez, Nancy Pavón Fuentes, Bárbara Estupiñán Díaz, Teresa Serrano Sánchez, Iván García Maeso and Luisa Rocha Arrieta
Affiliation:
Keywords: Epilepsy, inflammatory mediators, IL-1β, IL-6, TNF-α, neuroinflammation, temporal lobe epilepsy
Abstract: All common contributing factors to epilepsy such as trauma, malignancies and infections are accompanied by different levels of central nervous system inflammation that in turn have been associated with the occurrence of seizure. Emerging data from human brain tissue and experimental models of epilepsy support the proposed involvement of inflammation in epilepsy. Key mediators of this process include, among others: interleukin (IL) -1β, IL-6, tumor necrosis factor-α, adhesion molecules and component of complement. Recent advances suggest the involvement of specific inflammatory pathways in the pathogenesis of seizures in patients with pharmacoresistant temporal lobe epilepsy, highlighting the potential for new therapeutic strategies. This review provides an overview of the current knowledge on the relationship between inflammatory mediators and epilepsy. We also describe experimental and clinical evidence of inflammation in epilepsy with special emphasis on clinical aspects once the epileptogenic focus has been resected. Further insight into the complex role of inflammation in epileptogenesis may provide new treatment options.
Export Options
About this article
Cite this article as:
Lorigados Pedre Lourdes, Morales Chacón Lilia M, Orozco Suárez Sandra, Pavón Fuentes Nancy, Estupiñán Díaz Bárbara, Serrano Sánchez Teresa, García Maeso Iván and Rocha Arrieta Luisa, Inflammatory Mediators in Epilepsy, Current Pharmaceutical Design 2013; 19 (38) . https://dx.doi.org/10.2174/1381612811319380009
DOI https://dx.doi.org/10.2174/1381612811319380009 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
AMPA Receptor Antagonists for the Treatment of Stroke
Current Drug Targets - CNS & Neurological Disorders VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets Loop Gain and Sleep Disordered Breathing
Current Respiratory Medicine Reviews The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Molecular Properties Prediction, Docking Studies, and Antimicrobial Screening of 1,3,4-Thiadiazole and s-Triazole Derivatives
Current Computer-Aided Drug Design Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Impaired Functional Connectivity of the Thalamus in Alzheimer’ s Disease and Mild Cognitive Impairment: A Resting-State fMRI Study
Current Alzheimer Research Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
Current Drug Abuse Reviews Golgi Localization of Glycosyltransferases Involved in Ganglioside Biosynthesis
Current Drug Targets Evaluation of Anticonvulsants for Possible Use in Neuropathic Pain
Current Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Recent Advancement in Computer-Aided Drug Design
Current Pharmaceutical Design Cognitive Impairment and Mossy Fiber Sprouting in a Rat Model of Drug-resistant Epilepsy Induced by Lithium-pilocarpine
Current Neurovascular Research Connexin Modulators and Their Potential Targets under the Magnifying Glass
Current Medicinal Chemistry Positron Emission Tomography: Applications In Drug Discovery and Drug Development
Current Topics in Medicinal Chemistry Antiepileptics and the Treatment of Neuropathic Pain: Evidence from Animal Models
Current Pharmaceutical Design Seizures and Antiepileptic Drugs: From Pathophysiology to Clinical Practice
Current Pharmaceutical Design Monitoring Antiepileptic Drugs: A Level-Headed Approach
Current Neuropharmacology Introduction: P2 Receptors
Current Topics in Medicinal Chemistry